JP2012528845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528845A5 JP2012528845A5 JP2012513685A JP2012513685A JP2012528845A5 JP 2012528845 A5 JP2012528845 A5 JP 2012528845A5 JP 2012513685 A JP2012513685 A JP 2012513685A JP 2012513685 A JP2012513685 A JP 2012513685A JP 2012528845 A5 JP2012528845 A5 JP 2012528845A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- microparticles
- eudragit
- melt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000011859 microparticle Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- 229920001577 copolymer Polymers 0.000 claims 4
- 239000010419 fine particle Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003402 opiate agonist Substances 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 claims 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 claims 1
- 229920003156 Eudragit® RL PO Polymers 0.000 claims 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 claims 1
- 229920003160 Eudragit® RS PO Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 229960005126 tapentadol Drugs 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 229940125725 tranquilizer Drugs 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0909680.1 | 2009-06-05 | ||
| GBGB0909680.1A GB0909680D0 (en) | 2009-06-05 | 2009-06-05 | Dosage form |
| PCT/GB2010/050948 WO2010140007A2 (en) | 2009-06-05 | 2010-06-07 | Dosage form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528845A JP2012528845A (ja) | 2012-11-15 |
| JP2012528845A5 true JP2012528845A5 (https=) | 2013-07-25 |
| JP5635082B2 JP5635082B2 (ja) | 2014-12-03 |
Family
ID=40936947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513685A Expired - Fee Related JP5635082B2 (ja) | 2009-06-05 | 2010-06-07 | 剤形 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9814679B2 (https=) |
| EP (1) | EP2437729B1 (https=) |
| JP (1) | JP5635082B2 (https=) |
| KR (1) | KR101816130B1 (https=) |
| CN (2) | CN102481260A (https=) |
| AU (1) | AU2010255502B2 (https=) |
| BR (1) | BRPI1012004A2 (https=) |
| CA (1) | CA2764517C (https=) |
| EA (1) | EA022801B1 (https=) |
| ES (1) | ES2713957T3 (https=) |
| GB (1) | GB0909680D0 (https=) |
| IL (1) | IL216748A0 (https=) |
| MX (1) | MX2011012929A (https=) |
| MY (1) | MY173629A (https=) |
| NZ (1) | NZ596879A (https=) |
| SG (2) | SG176304A1 (https=) |
| WO (1) | WO2010140007A2 (https=) |
| ZA (1) | ZA201109221B (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| TWI473628B (zh) | 2009-07-22 | 2015-02-21 | 用於對氧化敏感之類鴉片藥劑之抗破壞劑型 | |
| WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
| CN103002881B (zh) | 2010-05-10 | 2015-09-02 | 欧洲凯尔特公司 | 载有活性剂的颗粒与额外活性剂的组合 |
| CA2798884C (en) | 2010-05-10 | 2016-09-13 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| AU2011252039B2 (en) * | 2010-05-10 | 2014-06-12 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| EP2635247B1 (en) | 2010-11-04 | 2016-12-14 | AbbVie Inc. | Method for producing monolithic tablets |
| US20120202838A1 (en) * | 2010-11-04 | 2012-08-09 | Abbott Laboratories | Drug formulations |
| GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
| AR084620A1 (es) * | 2010-12-28 | 2013-05-29 | Euro Celtique Sa | Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson |
| AU2012289764B2 (en) | 2011-07-29 | 2017-03-02 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| ES2648129T3 (es) | 2011-07-29 | 2017-12-28 | Grünenthal GmbH | Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento |
| CA2847611A1 (en) * | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| AR088250A1 (es) * | 2011-10-06 | 2014-05-21 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
| US20130129826A1 (en) * | 2011-11-17 | 2013-05-23 | Gruenenthal Gmbh | Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PL2838512T3 (pl) | 2012-04-18 | 2018-12-31 | Grünenthal GmbH | Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AU2013285988A1 (en) | 2012-07-06 | 2015-02-12 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
| CA2881144A1 (en) * | 2012-11-09 | 2014-05-09 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| AU2014273227B2 (en) * | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| CA3042642A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015071380A1 (en) | 2013-11-13 | 2015-05-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6403780B2 (ja) * | 2013-12-17 | 2018-10-10 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された持続放出性乱用抑止性丸剤 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015089530A1 (de) * | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon |
| CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
| EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| PT3164117T (pt) | 2014-07-03 | 2023-12-12 | SpecGx LLC | Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| US20160310437A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| MX2017013643A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |
| AU2016293508A1 (en) * | 2015-07-10 | 2018-02-01 | Sun Pharma Advanced Research Company Ltd. | Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| MX383740B (es) | 2016-05-13 | 2025-03-14 | Merck Patent Gmbh | Composición de extrusión fundida en caliente que usa un excipiente compresible directo como plastificante. |
| AU2018390826B2 (en) | 2017-12-20 | 2024-09-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| KR20240095253A (ko) * | 2021-10-27 | 2024-06-25 | 오11 바이오메디컬 게엠베하 | Co2의 제어된 생체내 흡수를 위한 코팅된 활성 성분 제형 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| DE19740983A1 (de) | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
| EP1183014B1 (en) | 1999-06-14 | 2003-10-08 | Cosmo S.p.A. | Controlled release and taste masking oral pharmaceutical compositions |
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| BR0212019A (pt) | 2001-08-06 | 2005-08-09 | Euro Celtique Sa | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem |
| PT1441700E (pt) | 2001-10-15 | 2007-10-29 | Ferring Bv | Método para a preparação de uma composição compreendendo ácido 5-aminosalicílico para uso em tratamento de colites ulcerosas ou da doença de crohn |
| HUE032656T2 (en) * | 2002-04-05 | 2017-10-30 | Euro Celtique Sa | Pharmaceutical composition containing oxicodone and naloxone |
| CA2499994C (en) * | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| EP1613333A1 (en) | 2003-04-04 | 2006-01-11 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| NZ545202A (en) | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
| GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| GEP20105052B (en) * | 2005-01-28 | 2010-07-26 | Euro Celtique Sa | Alcohol resistant dosage forms |
| US20070026025A1 (en) | 2005-04-12 | 2007-02-01 | Aquegel Cosmetics, Llc | Topical ointment and method for making and using same |
| US20070020339A1 (en) | 2005-07-20 | 2007-01-25 | Pharmorx Inc. | Compositions and methods for controlling abuse of medications |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| WO2007068615A2 (en) | 2005-12-14 | 2007-06-21 | F. Hoffmann-La Roche Ag | Hcv prodrug formulation |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| EP1935405A1 (en) | 2006-12-22 | 2008-06-25 | LEK Pharmaceuticals D.D. | Orally disintegrating tablets |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| GB2447898B (en) | 2007-03-24 | 2011-08-17 | Reckitt Benckiser Healthcare | A tablet having improved stability with at least two actives |
| CN102203169B (zh) * | 2008-11-12 | 2013-08-28 | 阿克佐诺贝尔国际涂料股份有限公司 | 窄粒度分布的聚合物分散体 |
| DE102009015702A1 (de) | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
| GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
-
2009
- 2009-06-05 GB GBGB0909680.1A patent/GB0909680D0/en not_active Ceased
-
2010
- 2010-06-07 NZ NZ596879A patent/NZ596879A/xx not_active IP Right Cessation
- 2010-06-07 WO PCT/GB2010/050948 patent/WO2010140007A2/en not_active Ceased
- 2010-06-07 SG SG2011089273A patent/SG176304A1/en unknown
- 2010-06-07 JP JP2012513685A patent/JP5635082B2/ja not_active Expired - Fee Related
- 2010-06-07 EA EA201171389A patent/EA022801B1/ru not_active IP Right Cessation
- 2010-06-07 KR KR1020127000058A patent/KR101816130B1/ko not_active Expired - Fee Related
- 2010-06-07 EP EP10725263.7A patent/EP2437729B1/en active Active
- 2010-06-07 MY MYPI2011005869A patent/MY173629A/en unknown
- 2010-06-07 MX MX2011012929A patent/MX2011012929A/es active IP Right Grant
- 2010-06-07 CN CN2010800344131A patent/CN102481260A/zh active Pending
- 2010-06-07 CA CA2764517A patent/CA2764517C/en not_active Expired - Fee Related
- 2010-06-07 SG SG10201402810XA patent/SG10201402810XA/en unknown
- 2010-06-07 CN CN201610970584.4A patent/CN106667919A/zh active Pending
- 2010-06-07 US US13/376,113 patent/US9814679B2/en active Active
- 2010-06-07 ES ES10725263T patent/ES2713957T3/es active Active
- 2010-06-07 BR BRPI1012004A patent/BRPI1012004A2/pt not_active Application Discontinuation
- 2010-06-07 AU AU2010255502A patent/AU2010255502B2/en not_active Ceased
-
2011
- 2011-12-04 IL IL216748A patent/IL216748A0/en unknown
- 2011-12-14 ZA ZA2011/09221A patent/ZA201109221B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528845A5 (https=) | ||
| HRP20170650T1 (hr) | Dozni oblik otporan na promjene | |
| US6194000B1 (en) | Analgesic immediate and controlled release pharmaceutical composition | |
| DE19901687B4 (de) | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung | |
| JP5501553B2 (ja) | 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程 | |
| EP1348429B1 (en) | Melt-extruded orally administrable opioid formulations | |
| JP5795138B2 (ja) | 一日に一回のオキシコドン製剤 | |
| JP3280810B2 (ja) | 持効性経口投与オピオイド製剤 | |
| CN1938004B (zh) | 包含吸附剂和不利剂的抗篡改剂型 | |
| HRP20180068T1 (hr) | Formulacije lijeka s produljenim oslobađanjem | |
| JP4669878B2 (ja) | 慢性閉塞性肺疾患（ｃｏｐｄ）の治療のためのオピオイド | |
| RU2010129907A (ru) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление | |
| US20070098795A1 (en) | Pharmaceutical formulation | |
| JP2013199488A5 (https=) | ||
| PH12018000176A1 (en) | Matrix for sustained invariant and independent release of active compounds | |
| JP2010090168A5 (https=) | ||
| DE20220910U1 (de) | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden | |
| JP2003513032A (ja) | 制御放出ヒドロコドン処方 | |
| CN103002881B (zh) | 载有活性剂的颗粒与额外活性剂的组合 | |
| RU2009111588A (ru) | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств | |
| SG172818A1 (en) | Abuse resistant melt extruded formulation having reduced alcohol interaction | |
| JP2008511604A5 (https=) | ||
| JP2014532078A5 (https=) | ||
| JP2009143964A5 (https=) | ||
| JP2016513721A5 (https=) |